Log In
Print
BCIQ
Print
Print this Print this
 

TC-DC, eltrapuldencel-T (CLBS20, NBS20) (formerly melapuldencel-T)

Also known as: DC-TC, Tumor Stem Cell Specific Dendritic Cell therapy (formerly NBS-20)

  Manage Alerts
Collapse Summary General Information
Company Caladrius Biosciences Inc.
DescriptionAutologous dendritic cells loaded with antigen from self-renewing, proliferating autologous tumor cells in GM-CSF
Molecular Target
Mechanism of ActionCell therapy
Therapeutic ModalityCell therapy: Non-stem cell
Latest Stage of DevelopmentPhase III
Standard IndicationMelanoma
Indication DetailsTreat metastatic melanoma; Treat recurrent stage III or IV metastatic melanoma
Regulatory Designation U.S. - Fast Track (Treat metastatic melanoma);
U.S. - Orphan Drug (Treat metastatic melanoma);
U.S. - Special Protocol Assessment (Treat metastatic melanoma)
Partner Cellular Biomedicine Group Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

4

$114.5M

$24.5M

$72.5M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today